1999
DOI: 10.1016/s0002-9394(99)00029-x
|View full text |Cite
|
Sign up to set email alerts
|

The treatment of refractory uveitis with intravenous immunoglobulin

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
29
1

Year Published

2002
2002
2019
2019

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 64 publications
(30 citation statements)
references
References 14 publications
0
29
1
Order By: Relevance
“…In another trial with therapy-resistant autoimmune uveitis, clinical benefit was seen in half of the patients treated with IGIV. 124 These data suggest that IGIV therapy might be an effective alternative for patients with this disease.…”
Section: Organ-specific Autoimmune Diseasementioning
confidence: 94%
“…In another trial with therapy-resistant autoimmune uveitis, clinical benefit was seen in half of the patients treated with IGIV. 124 These data suggest that IGIV therapy might be an effective alternative for patients with this disease.…”
Section: Organ-specific Autoimmune Diseasementioning
confidence: 94%
“…Results have been conflicting, but most studies have reported IV therapy to be less effective than oral (Jabs et al 2000;Rosenbaum 1994;Ozyazgan et al 1992), while a small number have concluded that IV pulse alone or in combination with low-dose corticosteroid treatment is as effective as oral with fewer side effects and decreased mortality (Khan et al 2013;Suelves et al 2013). The SITE Study demonstrated a trend for increased cancer-related mortality, leading to the authors' suggestion that even though IV delivery may be less effective for inflammation control, it may be preferable in order to reduce the risk of malignancy (Kempen et al 2008;Pujari et al 2010;Martin et al 1997).…”
Section: Cyclophosphamidementioning
confidence: 99%
“…Improvement in uveitis was found only in 5 patients, with sustained benefi t without additional immunosuppressive agents in only 2 patients [ 94 ] (EBM 3 D).…”
Section: Cyclophosphamidementioning
confidence: 99%